Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 15, 2015 - Issue 6
Submit an article Journal homepage
289
Views
20
CrossRef citations to date
0
Altmetric
Reviews

The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology

Natalia OlchanskiCenter for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USACorrespondence[email protected]
,
Yue ZhongCenter for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
,
Joshua T. CohenCenter for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
,
Cayla SaretCenter for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
,
Mohan BalaCenter for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA;Sanofi, Cambridge, MA, USA
&
Peter J. NeumannCenter for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
Pages 931-940 | Published online: 19 Oct 2015

Citations (20)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Monia Marchetti. (2017) Cost-effectiveness of kinase inhibitors for hematologic malignancies: a systematic and critical review. Expert Review of Pharmacoeconomics & Outcomes Research 17:5, pages 469-480.
Read now
Jacopo Giuliani, Andrea Remo & Andrea Bonetti. (2017) The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized-controlled trials of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating epidermal growth factor receptor mutations. Expert Review of Pharmacoeconomics & Outcomes Research 17:1, pages 5-8.
Read now

Articles from other publishers (18)

Hamraz Mokri, Ingelin Kvamme, Linda de Vries, Matthijs Versteegh & Pieter van Baal. (2022) Future medical and non-medical costs and their impact on the cost-effectiveness of life-prolonging interventions: a comparison of five European countries. The European Journal of Health Economics 24:5, pages 701-715.
Crossref
Siyu Ma, Natalia Olchanski, Joshua T. Cohen, Daniel A. Ollendorf, Peter J. Neumann & David D. Kim. (2022) The Impact of Broader Value Elements on Cost-Effectiveness Analysis: Two Case Studies. Value in Health 25:8, pages 1336-1343.
Crossref
Amy J Davidoff, Kaitlin Akif & Michael T Halpern. (2022) Research on the Economics of Cancer-Related Health Care: An Overview of the Review Literature. JNCI Monographs 2022:59, pages 12-20.
Crossref
Jacopo Giuliani. (2021) Cost-effectiveness of denosumab in preventing skeletal-related events in bone metastases. Journal of Oncology Pharmacy Practice 27:8, pages 2000-2003.
Crossref
Jacopo Giuliani, Francesco Fiorica, Giovanni Ponturo, Maurizio Azzurro, Andrea Ruzzenente & Andrea Bonetti. (2021) Dose-escalation strategy in refractory metastatic colorectal cancer: A change in terms of cost-effectiveness. Journal of Oncology Pharmacy Practice 27:4, pages 974-977.
Crossref
Ilia Stambler. 2021. Encyclopedia of Gerontology and Population Aging. Encyclopedia of Gerontology and Population Aging 4199 4204 .
Jacopo Giuliani & Andrea Bonetti. (2019) Immune-checkpoint inhibitors in head and neck squamous cell carcinoma: cost-efficacy in second-line treatment based on programmed death-ligand 1 (PD-L1) level. Oral Oncology 97, pages 143-145.
Crossref
Jacopo Giuliani & Andrea Bonetti. (2019) Palbociclib or Ribociclib in First-Line Treatment in Patients With Hormone Receptor–Positive/Human Epidermal Receptor 2–Negative Advanced or Metastatic Breast Cancer? A Perspective Based on Pharmacologic Costs. Clinical Breast Cancer 19:4, pages e519-e521.
Crossref
Michelle Tew, Philip Clarke, Karin Thursky & Kim Dalziel. (2019) Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients. PharmacoEconomics 37:7, pages 931-941.
Crossref
Jacopo Giuliani & Andrea Bonetti. (2019) Cost-Effectiveness of Second-Line Treatments for Metastatic Renal-Cell Carcinoma. Clinical Genitourinary Cancer 17:2, pages e258-e262.
Crossref
Ilia Stambler. 2019. Encyclopedia of Gerontology and Population Aging. Encyclopedia of Gerontology and Population Aging 1 6 .
Jacopo Giuliani & Andrea Bonetti. (2018) First-line therapies in metastatic colorectal cancer: integrating clinical benefit with the costs of drugs. International Journal of Colorectal Disease 33:11, pages 1505-1516.
Crossref
Jacopo Giuliani & Andrea Bonetti. (2018) Nivolumab Is a Cost-Effective Second-Line Treatment for Metastatic Renal-Cell Carcinoma. Clinical Genitourinary Cancer 16:3, pages e557-e562.
Crossref
Jacopo Giuliani & Andrea Bonetti. (2018) Regorafenib or Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer? A Perspective on the Basis of Pharmacological Costs. Clinical Colorectal Cancer 17:2, pages e381-e383.
Crossref
Ilia Stambler. 2018. Reference Module in Biomedical Sciences. Reference Module in Biomedical Sciences.
Jacopo Giuliani & Andrea Bonetti. (2017) The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer. International Journal of Gynecological Cancer 27:9, pages 1872-1876.
Crossref
Jacopo Giuliani & Andrea Bonetti. (2016) The Pharmacological Costs of First-Line Therapies in Unselected Patients With Advanced Colorectal Cancer: A Review of Published Phase III Trials. Clinical Colorectal Cancer 15:4, pages 277-284.
Crossref
Jacopo Giuliani & Andrea Bonetti. (2016) The Pharmacological Costs of Complete Liver Resections in Unselected Advanced Colorectal Cancer Patients: Focus on Targeted Agents. A Review of Randomized Clinical Trials. Journal of Gastrointestinal Cancer 47:4, pages 341-350.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.